Cargando…

Metabolomics in oncology

BACKGROUND: Oncogenic transformation alters intracellular metabolism and contributes to the growth of malignant cells. Metabolomics, or the study of small molecules, can reveal insight about cancer progression that other biomarker studies cannot. Number of metabolites involved in this process have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Suri, Gurparsad Singh, Kaur, Gurleen, Carbone, Giuseppina M., Shinde, Dheeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026298/
https://www.ncbi.nlm.nih.gov/pubmed/36811317
http://dx.doi.org/10.1002/cnr2.1795
_version_ 1784909513073098752
author Suri, Gurparsad Singh
Kaur, Gurleen
Carbone, Giuseppina M.
Shinde, Dheeraj
author_facet Suri, Gurparsad Singh
Kaur, Gurleen
Carbone, Giuseppina M.
Shinde, Dheeraj
author_sort Suri, Gurparsad Singh
collection PubMed
description BACKGROUND: Oncogenic transformation alters intracellular metabolism and contributes to the growth of malignant cells. Metabolomics, or the study of small molecules, can reveal insight about cancer progression that other biomarker studies cannot. Number of metabolites involved in this process have been in spotlight for cancer detection, monitoring, and therapy. RECENT FINDINGS: In this review, the “Metabolomics” is defined in terms of current technology having both clinical and translational applications. Researchers have shown metabolomics can be used to discern metabolic indicators non‐invasively using different analytical methods like positron emission tomography, magnetic resonance spectroscopic imaging etc. Metabolomic profiling is a powerful and technically feasible way to track changes in tumor metabolism and gauge treatment response across time. Recent studies have shown metabolomics can also predict individual metabolic changes in response to cancer treatment, measure medication efficacy, and monitor drug resistance. Its significance in cancer development and treatment is summarized in this review. CONCLUSION: Although in infancy, metabolomics can be used to identify treatment options and/or predict responsiveness to cancer treatments. Technical challenges like database management, cost and methodical knowhow still persist. Overcoming these challenges in near further can help in designing new treatment régimes with increased sensitivity and specificity.
format Online
Article
Text
id pubmed-10026298
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-100262982023-03-21 Metabolomics in oncology Suri, Gurparsad Singh Kaur, Gurleen Carbone, Giuseppina M. Shinde, Dheeraj Cancer Rep (Hoboken) Reviews BACKGROUND: Oncogenic transformation alters intracellular metabolism and contributes to the growth of malignant cells. Metabolomics, or the study of small molecules, can reveal insight about cancer progression that other biomarker studies cannot. Number of metabolites involved in this process have been in spotlight for cancer detection, monitoring, and therapy. RECENT FINDINGS: In this review, the “Metabolomics” is defined in terms of current technology having both clinical and translational applications. Researchers have shown metabolomics can be used to discern metabolic indicators non‐invasively using different analytical methods like positron emission tomography, magnetic resonance spectroscopic imaging etc. Metabolomic profiling is a powerful and technically feasible way to track changes in tumor metabolism and gauge treatment response across time. Recent studies have shown metabolomics can also predict individual metabolic changes in response to cancer treatment, measure medication efficacy, and monitor drug resistance. Its significance in cancer development and treatment is summarized in this review. CONCLUSION: Although in infancy, metabolomics can be used to identify treatment options and/or predict responsiveness to cancer treatments. Technical challenges like database management, cost and methodical knowhow still persist. Overcoming these challenges in near further can help in designing new treatment régimes with increased sensitivity and specificity. John Wiley and Sons Inc. 2023-02-21 /pmc/articles/PMC10026298/ /pubmed/36811317 http://dx.doi.org/10.1002/cnr2.1795 Text en © 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Suri, Gurparsad Singh
Kaur, Gurleen
Carbone, Giuseppina M.
Shinde, Dheeraj
Metabolomics in oncology
title Metabolomics in oncology
title_full Metabolomics in oncology
title_fullStr Metabolomics in oncology
title_full_unstemmed Metabolomics in oncology
title_short Metabolomics in oncology
title_sort metabolomics in oncology
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026298/
https://www.ncbi.nlm.nih.gov/pubmed/36811317
http://dx.doi.org/10.1002/cnr2.1795
work_keys_str_mv AT surigurparsadsingh metabolomicsinoncology
AT kaurgurleen metabolomicsinoncology
AT carbonegiuseppinam metabolomicsinoncology
AT shindedheeraj metabolomicsinoncology